Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01756352 : FET-PET for Evaluation of Response of Recurrent GBM to Avastin
PhasePhase 2
AgesMin: 18 Years Max: 85 Years
Eligibility
Inclusion Criteria:

- 1. GBM patients with changes on MRI suggestive of recurrence who have not yet
initiated antiangiogenic therapy. 2. Age ? 18 3. Anticipated survival >3 months 4.
Able to give informed consent 5. Capable of undergoing scan without the need for
sedation or general anesthesia.

Exclusion Criteria:

1. Active intracranial infection or nonglial brain mass.

2. Recent large intracranial hemorrhage (<1 month; size to be determined by principal
investigator)

3. Pregnant or nursing. Quantitative serum hCG testing will be performed prior to the
initial and each -subsequent FET- PET scan on all females of childbearing potential.
Our BWH Radiation Safety Committee and Partners IRB requires stat serum ß-hcG
pregnancy tests.

4. Patient lives too far from BWH and/or is unwilling/ unable to return for scheduled
imaging visits.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01756352      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740